┌──────────────────────────────────────────────────────────────┐ RECORD TYPE ......... SUBJECT FILE SUBJECT TYPE ........ ORG FILE OPENED ......... 2026-07-05 17:23 UTC APPEARANCES ......... 5 ANNOTATIONS KNOWN ALIASES ....... 1 └──────────────────────────────────────────────────────────────┘
Imipramine
ALSO APPEARS AS
- Imipramine
APPEARS IN THE MARGINS OF
- Study 329 Adverse Event Data Exclusion and FDA Disclosure
Study 329, a clinical trial of paroxetine (Paxil) in adolescents with major depressive disorder, was conducted from 1994 to 1998 and initially published in 2001 by Keller and colleagues. This original…
- FDA Internal Review of Study 329 Adverse Events Pre-RIAT
Study 329 was a clinical trial conducted by SmithKline Beecham (now GlaxoSmithKline) between 1994 and 1998, investigating the efficacy and safety of paroxetine and imipramine in adolescents with major…
- Study 329 RIAT Reanalysis: Previously Unreported Adverse Events
Study 329 was an industry-sponsored clinical trial of paroxetine (Paxil/Seroxat) for adolescent depression, originally published in 2001. The original publication claimed the drug was generally well-t…
- Study 329: Contents of Appendix H and GSK's Data Provision to RIAT
Study 329 was a clinical trial sponsored by SmithKline Beecham (now GSK) investigating paroxetine in adolescents with depression. The original published results by Keller et al. in 2001 were subsequen…
- Study 329's Impact on Adolescent Antidepressant Prescriptions
Study 329, a clinical trial evaluating paroxetine and imipramine for adolescent major depression, was originally published in 2001, claiming efficacy and safety for paroxetine [1]. This original publi…